Canaccord analyst Dewey Steadman said the recent pullback in Scynexis represents a compelling long-term entry point. He calls Scynexis a unique story in the infectious disease space with a chance for a large retail indication with its ibrexafungerp WC program alongside important life-saving applications for refractory fungal infections with the same product. Steadman reiterated his Buy rating and $4 price target on Scynexis shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.